Topaz Biosciences, Inc.
Publicly observedEmeryville, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Emeryville | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Topaz Biosciences, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | X1VTPJFPY874 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant15 Aug 2023Publicly observed
NIH SBIR/STTR award: Development of novel endolysins targeting Cutibacterium acnes to treat acne vulgaris
USD 576,499.00 · National Institute of Arthritis and Musculoskeletal and Skin Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant15 Aug 2023Publicly observed
NIH SBIR/STTR award: Development of novel endolysins targeting Cutibacterium acnes to treat acne vulgaris
USD 1,469,201.00 · National Institute of Arthritis and Musculoskeletal and Skin Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.